(+)-Irinotecan

Irinotecan exhibits significant biological activity through its mechanism of action as a topoisomerase I inhibitor. The active metabolite SN-38 has been shown to be approximately 1000 times more potent than irinotecan itself in inhibiting topoisomerase I. This inhibition leads to cell cycle arrest during the S and G2 phases, ultimately resulting in apoptosis of cancer cells. The compound's effectiveness can be influenced by genetic polymorphisms in metabolic enzymes such as uridine diphosphate glucuronosyltransferase 1A1, which can affect drug toxicity and efficacy.

Please email your required order quantity and detailed technical specifications to sales@.
Our sales team will promptly prepare an accurate quotation for your bulk order and provide a comprehensive pricing proposal.

All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.